Glenmark Life Sciences Ltd (GLS) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of Glenmark Life Sciences Ltd ₹463, price ₹1,372, upside -66.3%, quality 65 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Glenmark Life Sciences Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 1, 2026.
How to read this chart
60‑month range ₹343.59 – ₹1,444 · fair‑value band ₹304.67 – ₹662.50 · the ₹1,372 price screens above the ₹462.52 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 1, 2026.
Follow Glenmark Life Sciences in your weekly email
Every Wednesday you see whether Glenmark Life Sciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Alivus Life Sciences Limited engages in the development, manufacture, and marketing of non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India. The company offers various APIs, such as olmesartan, telmisartan, perindopril, atovaquone, solifenacin, mirabegron, sitagliptin, zonisamide, adapalene, and rosuvastatin.
Show more
Alivus Life Sciences Limited engages in the development, manufacture, and marketing of non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India. The company offers various APIs, such as olmesartan, telmisartan, perindopril, atovaquone, solifenacin, mirabegron, sitagliptin, zonisamide, adapalene, and rosuvastatin. It also provides contract development and manufacturing services to a range of multinational corporations and specialty companies. The company's APIs are used in various therapeutic segments, including cardiovascular disease, central nervous system disorders, diabetes, gastrointestinal health, oncology, pain management, and anti-infectives. It also exports its products to Europe, North America, Latin America, Japan, and internationally. The company was formerly known as Glenmark Life Sciences Limited and changed its name to Alivus Life Sciences Limited in December 2024. The company was incorporated in 2011 and is based in Mumbai, India. Alivus Life Sciences Limited is a subsidiary of Nirma Limited.
Stock analysis
Glenmark Life Sciences Ltd (GLS) currently trades at ₹1,372, while our model-based Fair Value estimate is ₹462.52, 66.3% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ₹693.69 per share, and 0 of the 25 models we run sit above the ₹1,372 price.
Bear case: the Asset-Based group reads lowest at ₹127.53, and 25 of the 25 models stay below the price. Evidence for this calculation is high.
Scenario range: ₹304.67 (bear) to ₹662.50 (bull), the price of ₹1,372 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 65/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Glenmark Life Sciences Ltd reported revenue of ₹21.8B in FY2024 versus ₹15.4B in FY2020, a compound +9.2%/yr. Reported net income was ₹4.7B in FY2024, compounding +10.7%/yr from FY2020.
Key figures
Market cap ₹168B (≈ $1.7B) · P/E ratio 38.2 · P/S ratio 8.23 · EPS (TTM) ₹35.92 · Dividend yield 2.1% · Net margin 21.6% · Return on equity 17.2% · Return on assets (EBIT) 24.3%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (medium confidence).
What moves the price
The share trades about 5% below its 52-week high and 59% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at −66%, GLS screens richer than that median.
Fair Value models
Bear ₹304.67Fair Value ₹462.52Bull ₹662.50
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.71/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+1.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.0%
’20
’21
’22
’23
’24
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+10.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year+8.5%
Dividend (yield on the price)2.1%
Profit margin 2020 to 2024 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.29% → 29%
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+37.5%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (India: IMF forecast 4.1% a year to 2030, 4.7% from 2016 to 2025) that is about +32.1% a year for the price.
Compare Glenmark Life Sciences Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 585 stocks
Beats the industry median on 6/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score65 · Top 25%
Fair Value upside−66.3% · Bottom 25%
Profitability
Return on equity (TTM)17.2% · Top 25%
Return on assets11.4% · Top 25%
Net margin (TTM)19.2% · Top 25%
Operating margin (TTM)23.5% · Top 25%
Growth and dividend
Revenue growth−14.9% · Bottom 25%
Dividend yield (TTM)2.1% · Above median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/E (TTM)38.2× · Pricier than median
P/B7.21× · Priciest 25%
P/S (TTM)7.63× · Priciest 25%
P/FCF59.1× · Priciest 25%
EV/EBITDA27.4× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 14
FUTURE (revenue growth)0· sector 24
PAST (return on equity)69· sector 28
HEALTH (low debt)0· sector 96
DIVIDEND (yield)41· sector 31
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Glenmark Life Sciences Ltd Fair Value". https://www.fairvalue-calculator.com/stock/GLS
Frequently asked questions
Is Glenmark Life Sciences Ltd (GLS) overvalued or undervalued?
As of Oct 1, 2026, our model estimates a fair value of ₹462.52 versus a price of ₹1,372, about −66% upside (overvalued).
What is the fair value of GLS?
Our model-based fair value for Glenmark Life Sciences Ltd is ₹462.52 (as of Oct 1, 2026), built from audited fundamentals. The current price: ₹1,372.
What is the quality score of GLS?
Glenmark Life Sciences Ltd has a Quality Score of 65/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Glenmark Life Sciences Ltd (GLS)?
Our model-based price target is the fair value of ₹462.52 (as of Oct 1, 2026) from 25 valuation models. Cautious scenario ₹304.67, optimistic scenario ₹662.50. It is a calculation from audited fundamentals, not an analyst target.
What is the Glenmark Life Sciences Ltd stock forecast for 2026?
Our models put fair value at ₹462.52, about −66% upside versus a price of ₹1,372 (overvalued). Cautious scenario ₹304.67, optimistic scenario ₹662.50. The calculation is refreshed regularly with new filings.
What is the revenue of Glenmark Life Sciences Ltd (GLS)?
Glenmark Life Sciences Ltd reported trailing-twelve-month revenue of about ₹22.0B (latest available figure, as of Oct 1, 2026).
Does Glenmark Life Sciences Ltd pay a dividend?
Glenmark Life Sciences Ltd currently shows a dividend yield of about 2.07% relative to its recent price (as of Oct 1, 2026).
What growth is priced into Glenmark Life Sciences Ltd (GLS)?
For today's price to be fair in a discounted-cash-flow model, Glenmark Life Sciences Ltd would have to grow free cash flow by +37.5 % per year for five years (discount rate 12.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 4 years revenue grew +9.2 % per year. As of Oct 1, 2026.
What discount rate (WACC) does the fair value of GLS use?
Our models discount Glenmark Life Sciences Ltd at 12.4 %: a base by market capitalisation (small), damped by beta 0.16, country premium for India. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Glenmark Life Sciences Ltd that is +37.5 % per year a year over ten years, using the same discount rate (12.4 %) and the same formula as our fair value.
How much growth has Glenmark Life Sciences Ltd (GLS) delivered so far?
Over the past 4 years revenue at Glenmark Life Sciences Ltd grew +9.2 % a year. The price currently implies +37.5 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Glenmark Life Sciences Ltd (GLS) growing?
The median revenue growth in the sector is +4.6 % a year. That is the yardstick for the growth priced into Glenmark Life Sciences Ltd (+37.5 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Glenmark Life Sciences Ltd (GLS)?
The free-cash-flow yield on the price is 1.69 %: that much free cash flow Glenmark Life Sciences Ltd produces per unit of market value. When it exceeds the discount rate of our models (12.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Glenmark Life Sciences Ltd (GLS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Glenmark Life Sciences Ltd it is ₹462.52 per share (as of Oct 1, 2026), against a price of ₹1,372. It is the blended result of 25 valuation models (cash flow, earnings, asset, dividend).
Is Glenmark Life Sciences Ltd stock overvalued or undervalued in 2026?
As of Oct 1, 2026, GLS trades above its calculated fair value: price ₹1,372, fair value ₹462.52, a gap of about −66% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of GLS?
No. The price is what the market pays today (₹1,372); the fair value is what the company's own numbers justify (₹462.52). For Glenmark Life Sciences Ltd the two are ₹909.88 per share apart. That gap is exactly why we show both numbers side by side.
How much is Glenmark Life Sciences Ltd worth?
The market values Glenmark Life Sciences Ltd at about ₹168B (market capitalisation, as of Oct 1, 2026). Per share that is ₹1,372; our models calculate a fair value of ₹462.52 per share.
What do the bullish and bearish scenarios say about GLS?
Our models span a range for Glenmark Life Sciences Ltd: cautious scenario ₹304.67, base ₹462.52, optimistic ₹662.50 per share (as of Oct 1, 2026, price ₹1,372). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of GLS?
Glenmark Life Sciences Ltd trades at a price-to-earnings ratio of 38.2 (as of Oct 1, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹462.52 is built from several models across several years. Other multiples: P/B 7.2, P/S 7.6, EV/EBITDA 27.4.
How solid is the balance sheet of Glenmark Life Sciences Ltd (GLS)?
Balance-sheet figures for Glenmark Life Sciences Ltd (as of Oct 1, 2026): return on equity 17.2%. They feed the Quality Score of 65/100, which measures business quality independently of the share price.
How far is GLS from its 52-week high?
Glenmark Life Sciences Ltd trades at ₹1,372, about 5% below its 52-week high of ₹1,444 and 59% above the low of ₹861.80 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of ₹462.52 is for.
Which stocks are comparable to Glenmark Life Sciences Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Glenmark Life Sciences Ltd stock attractive at the current price?
The data as of Oct 1, 2026: price ₹1,372, calculated fair value ₹462.52 (−66%), Quality Score 65/100, from 25 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of GLS calculated?
We run Glenmark Life Sciences Ltd through 25 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹462.52, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Glenmark Life Sciences Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Glenmark Life Sciences Ltd (GLS)?
The closing price on Oct 1, 2026 was ₹1,372. Our model-based fair value is ₹462.52, about −66% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Glenmark Life Sciences Ltd right now?
The price sits above even our optimistic bull case (₹662.50). The favourable scenario is already priced in. Solid but not exceptional quality (65/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (₹304.67 to ₹662.50) leaves room in how you read the outcome.
Key figures of Glenmark Life Sciences Ltd
How large is the market capitalisation of Glenmark Life Sciences Ltd (GLS)?
The market capitalisation of Glenmark Life Sciences Ltd is ₹168B (≈ $1.7B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Glenmark Life Sciences Ltd (GLS)?
The price-to-sales ratio of Glenmark Life Sciences Ltd is 8.23 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Glenmark Life Sciences Ltd (GLS)?
Earnings per share at Glenmark Life Sciences Ltd are ₹35.92 (price ÷ EPS = P/E 38.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Glenmark Life Sciences Ltd (GLS)?
The dividend yield of Glenmark Life Sciences Ltd is 2.1% (payout 79.2%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Glenmark Life Sciences Ltd (GLS)?
The net margin of Glenmark Life Sciences Ltd is 21.6% (fiscal year 2024). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Glenmark Life Sciences Ltd (GLS)?
The return on equity (ROE) of Glenmark Life Sciences Ltd is 17.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Glenmark Life Sciences Ltd (GLS)?
On an EBIT basis the return on assets of Glenmark Life Sciences Ltd is 24.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Glenmark Life Sciences Ltd (GLS)?
The operating margin of Glenmark Life Sciences Ltd is 23.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Glenmark Life Sciences Ltd (GLS)?
Revenue at Glenmark Life Sciences Ltd is growing −14.9% versus a year earlier (3y avg +5.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Glenmark Life Sciences Ltd (GLS)?
Earnings per share at Glenmark Life Sciences Ltd are growing −20.0% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch Glenmark Life Sciences Ltd in the live analysis
One click puts Glenmark Life Sciences Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
